Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

foslinanib

An orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry activities. Upon oral administration, foslinanib targets and inhibits the formation of vasculogenic mimicry (VM; vascular mimicry). By destroying the VM channels and network, cancer cells are devoid of perfusion leading to an induction of cancer cell apoptosis and inhibition of cancer cell proliferation. VM is associated with tumor metastasis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	CVM 1118 CVM-1118 CVM1118 TRX 818 TRX-818 TRX818
Chemical structure:	4(1H)-quinolinone, 2-(3-fluorophenyl)-6-methoxy-5-(phosphonooxy)-

foslinanib

Search NCI's Drug Dictionary